Latest Healthcare News

Trajan Group Holdings reports steady market demand and successful cost initiatives in H2 FY26 but warns of a $4 million revenue hit from Australian dollar appreciation.

Cryosite Limited delivered a robust 22% revenue increase and 28% EBITDA growth for the ten months to April 2026, powered by expanding clinical trial activity and infrastructure upgrades.

Memphasys has landed a major 1,000-cartridge order for its Felix™ System from MENA distributor ITL, with strong repeat demand from Qatar’s Hamad Medical Corporation and new market expansions into UAE, Kuwait, and soon Turkey.

Biome Australia has launched a multi-centre clinical trial for its proprietary probiotic BMB18, adding a prestigious Greek university to its research network and commencing recruitment within the expected timeline.

EMVision's First Responder Brain Scanner has proven its operational feasibility in aeromedical settings with the Royal Flying Doctor Service, de-risking rural stroke diagnosis and supporting progression to commercial production.

CleanSpace Holdings expects modest revenue growth for FY26, hindered by product certification delays and global market challenges, while maintaining a strong cash position and preparing a new respirator launch.

Skin Elements Limited has lodged an application with the Takeovers Panel alleging undisclosed voting power exceeding 20% via a private placement, raising questions about shareholder rights ahead of critical board spill meetings.

Nexalis Therapeutics (ASX: NX1) has voluntarily suspended trading of its shares pending a material announcement on its existing debt funding facility, extending a recent trading halt. The suspension is set to last until the earlier of the announcement release or resumption of trading on 28 May 2026.

Osteopore has secured Hainan FDA approval to clinically use and sell its custom orthopaedic devices at Shanghai Ruijin Hospital’s Hainan branch, marking a key step towards wider China market access. The company has scheduled its first patient surgery for June 2026.

Aroa Biosurgery posted a breakout FY26, beating revenue and EBITDA guidance with a 54% surge in Myriad sales. The company plans significant investments in FY27 to accelerate growth and capitalise on new market opportunities.

Ryman Healthcare reported a substantial reduction in net loss for FY26 alongside its first positive free cash flow in over a decade, driven by operational improvements, refinancing, and land divestments.

Fisher & Paykel Healthcare posted a 14% revenue increase to NZ$2.31 billion and a 24% rise in net profit to NZ$468.5 million for FY2026, driven by strong hospital product sales and ongoing innovation.